ReviewCost effectiveness and resource allocation : C/E2026
A systematic review of data sources used for socioeconomic impact assessment of antimicrobial resistance from a One Health perspective: a lack of representative data.
Review in Cost effectiveness and resource allocation : C/E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionAntimicrobial resistance (AMR) has become one of global health threats, having not only clinical impact but also socioeconomic impact. Despite numerous studies attempting to estimate the impact of AMR, there is limited evidence regarding its overall impact from a One Health perspective. As data sources are crucial for accurately estimating the impact, this systematic review aims to identify the data sources used in socioeconomic impact studies of AMR from a One Health perspective. MATERIAL AND
methodsA systematic literature review of studies providing new estimates of AMR impact (“index studies”) from 2010 to 2022 was conducted. Subsequently, we retrieved the “data sources” for the key parameters used in the index studies. The maximum of five data sources for each index study was set to select the parameters with the highest impact on the estimates. The characteristics and details of data sources were extracted.
resultsA total of 233 index studies were identified, and 395 data sources were further retrieved and extracted. The majority of data sources were from academic journals (89.4%) published during 2011 to 2020 (70.1%). Approximately half of the data sources were from high-income countries located in the Americas (32.4%) and European (23.0%) regions. Almost all data sources focused on humans (98.2%). There were only five data sources in animals and two data sources focusing on both humans and animals. No data source involving the environment was identified.
conclusionMost socioeconomic impact studies appropriately utilize up-to-date data sources from the same setting. However, there are some limitations including a disproportion of data from high-income countries, particularly the Americas and European regions. There is also a lack of data addressing AMR in animals and the environment. Thus, future AMR studies concerning pathogens and regions significantly affected by AMR are critical for achieving more comprehensive and representative data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.